Literature DB >> 8069551

The distribution of free and non-ionic vesicular sodium stibogluconate in the dog.

M Collins1, K C Carter, A J Baillie, J O'Grady.   

Abstract

The pharmacokinetics and tissue distribution of antimony after the administration of sodium stibogluconate in a free form or entrapped in vesicles prepared from non-ionic surfactant were studied in the dog. Animals were given either one or two intravenous bolus injection(s) equivalent to 45 mg Sb kg-1 as free drug or 0.625 or 0.685 mg Sb kg-1 as vesicular drug. Blood samples were taken at various times after dosing and antimony levels in various tissues were determined at 3 h, 48 h and 6 days after dosing. After free stibogluconate antimony clearance from the blood occurred in a rapid elimination phase with a blood half-life of 0.58 +/- 0.08 h. This rapid elimination phase did not occur after vesicular drug. Both drug preparations gave similar antimony levels in the spleen, liver and femur and humerus bone marrow at all time points assessed even though the vesicular dose was one-seventieth of the free drug dose. After the free drug there was marked urinary excretion of antimony and, as a result, increased kidney loading at the expense of other tissue. Vesicle-mediated drug delivery suppressed renal excretion and a much greater proportion of the antimony dose was recovered from tissue than was obtained after free drug. A hypothesis is presented to account for the differences in tissue antimony concentrations produced by the two formulations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8069551     DOI: 10.3109/10611869308996069

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  5 in total

1.  Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.

Authors:  Raul R Ribeiro; Eliane P Moura; Vitor M Pimentel; Weverton M Sampaio; Sydnei M Silva; Dante A Schettini; Cintia F Alves; Ferdinan A Melo; Wagner L Tafuri; Cynthia Demicheli; Maria N Melo; Frédéric Frézard; Marilene S M Michalick
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

2.  Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.

Authors:  K C Carter; A B Mullen; S Sundar; R T Kenney
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

3.  Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals.

Authors:  J Nieto; J Alvar; A B Mullen; K C Carter; C Rodríguez; M I San Andrés; M D San Andrés; A J Baillie; F González
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

4.  The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.

Authors:  K C Carter; A J Baillie; A B Mullen
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

Review 5.  Pentavalent antimonials: new perspectives for old drugs.

Authors:  Frédéric Frézard; Cynthia Demicheli; Raul R Ribeiro
Journal:  Molecules       Date:  2009-06-30       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.